WO2026033244 - ANTIBODY COMPOSITIONS FOR REDUCING CROSS-REACTIVITY
National phase entry is expected:
Publication Number
WO/2026/033244
Publication Date
12.02.2026
International Application No.
PCT/IB2024/057572
International Filing Date
05.08.2024
Title **
[English]
ANTIBODY COMPOSITIONS FOR REDUCING CROSS-REACTIVITY
[French]
COMPOSITIONS D'ANTICORPS POUR RÉDUIRE LA RÉACTIVITÉ CROISÉE
Applicants **
BECKMAN COULTER, INC.
Inventors
MONSONIS, Frederic
SCIFO, Caroline
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2119 | |
| EPO | Filing, Examination, Granting | 8771 | |
| Japan | Filing, Examination, Granting | 2153 | |
| South Korea | Filing, Examination, Granting | 1978 | |
| USA | Filing, Examination, Granting | 7140 |
Total:
22,161
Contact Us
Abstract[English]
The invention relates to antibody compositions for reducing cross reactivity between antibodies specific to related antigens, methods using such compositions and kits comprising such compositions.[French]
L'invention concerne des compositions d'anticorps pour réduire la réactivité croisée entre des anticorps spécifiques d'antigènes apparentés, des procédés utilisant de telles compositions et des kits comprenant de telles compositions.